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A B S T R A C T   
Multifocal micronodular pneumocyte hyperplasia (MMPH) is a benign proliferation of alveolar type II cells 
presenting as multiple pulmonary nodules at chest imaging, which is frequently seen in patients with tuberous 
sclerosis complex (TSC). We report a case of a woman with TSC and MMPH who received everolimus, a 
mechanistic target of rapamycin (mTOR) inhibitor, for the treatment of a subependymal giant cell astrocytoma 
(SEGA). After 3 months of therapy, a remarkable decrease in density of all pulmonary MMPH lesions was 
observed, without any change in size. This shows that everolimus is active on MMPH similarly to its effects on 
SEGA, renal angiomyolipomas, and pulmonary lymphangioleiomyomatosis in TSC, and suggests that the dys-
regulated activation of mTOR which characterizes TSC also plays a role in the pathogenesis of MMPH.   
1. Introduction 
Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by 
inactivating mutations in the tumor suppressor genes TSC1 or TSC2 
coding for hamartin and tuberin [1]. These proteins form an intracel-
lular complex that inhibits the mechanistic target of rapamycin (mTOR), 
a key regulator of cell growth and proliferation. In TSC, the loss of 
hamartin or tuberin leads to constitutive activation of mTOR and 
abnormal cell growth and proliferation, resulting in development of 
hamartomas in various organs such as subependymal giant cell astro-
cytomas (SEGAs) and renal angiomyolipomas (AMLs) [1]. Pulmonary 
manifestations of TSC include lymphangioleiomyomatosis (LAM), a rare 
condition characterized by cystic destruction of lung parenchyma, and 
multifocal micronodular pneumocyte hyperplasia (MMPH), a benign 
proliferation of alveolar type II cells presenting as multiple pulmonary 
nodules scattered throughout the lungs. 
Pharmacological inhibition of mTOR with sirolimus and everolimus 
leads to decrease in size of SEGAs and renal AMLs in TSC [2,3], and 
stabilizes lung function in LAM [4], but its effect on MMPH is unclear. 
2. Case report 
A 20-year old woman was diagnosed at birth as having TSC. She 
developed epilepsy at the age of 15 months. Brain magnetic resonance 
imaging (MRI) revealed a SEGA and cortical tubers. Other typical 
manifestations that appeared progressively over time included multiple 
renal AMLs, cardiac rhabdomyoma, facial angiofibromas, hypo-
melanotic macules and ungueal fibromas. No genetic testing was per-
formed in the patient, but genetic analysis in both parents did not detect 
any TSC1 or TSC2 mutation. 
At the age of 14, the gradual growth of the SEGA led to hydro-
cephalus, which was treated by ventriculoperitoneal shunting and 
fenestration of the septum pellucidum. Due to recurrent intracranial 
hypertension, incomplete surgical removal of the tumor was performed 
3 months later, and the diagnosis of SEGA was confirmed at 
histopathology. 
At the age of 15, a growing right renal mass suspect of AML led to 
selective arterial renal embolization and concomitant needle biopsy. 
Despite careful histopathological examination and external review, it 
was not possible to discriminate between epithelioid AML and papillary 
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Fig. 1. Chest HRCT at 0, 6, 12, 18 and 36 months (mo): stability in size, shape and density of numerous small pulmonary nodules with a random distribution on the 4 
first HRCTs, followed by a significant decrease in density of all pulmonary nodules at 36 months, i.e. 3 months after everolimus initiation (A). Similar observation 
focused on selected nodules in the right upper lobe (B) and left lower lobe (C). Follow-up of dimensions (long and short axis) in millimeters (mm) and density using 
Hounsfield Unit (HU) values of the 8 most easily perceptible solid nodules, showing no change in size over time before (first 4 HRCTs) and after (last HRCT) 
everolimus initiation, but a decrease in density on the last HRCT performed 3 months after treatment onset (D). 
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renal cell carcinoma, and regular imaging follow-up was instituted. A 
chest high-resolution CT (HRCT) revealed numerous small pulmonary 
nodules randomly distributed throughout both lungs. 
At first visit to our Department, the patient was a non-smoker and 
had no respiratory symptoms. Lung auscultation was unremarkable. 
Pulmonary function tests showed normal lung volumes and carbon 
monoxide transfer coefficient. There was no feature suggesting an 
infection, including tuberculosis. In the absence of cystic lung lesions on 
HRCT, LAM was ruled out. Follow-up HRCT at 6, 12 and 18 months 
showed stability in the number, size and density of all pulmonary nod-
ules, thus reducing the likelihood of metastatic disease and suggesting 
MMPH. Moreover, the renal mass remained stable for 2 years after 
embolization, thus reinforcing the hypothesis of AML. 
At the age of 18, owing to progressive SEGA growth and increased 
seizure frequency, the patient was started on everolimus 10 mg daily. 
The treatment was well tolerated. Brain MRI after 3 months showed a 
significant reduction in SEGA size, which subsequently remained stable 
at 8 and 11 months of treatment. A follow-up chest HRCT performed 3 
months after everolimus initiation (and 3 years after the first thoracic 
imaging) showed a remarkable decrease in density of all pulmonary 
MMPH lesions, without obvious change in size (Fig. 1A–C). We 
measured the diameter and density of the 8 most easily perceptible solid 
nodules on the 4 HRCT performed before everolimus, and the last one on 
everolimus. As shown in Fig. 1D, long and short axis (axial view) of all 8 
nodules did not change over time either before or after everolimus 
therapy. In contrast, the density of all 8 nodules decreased after ever-
olimus initiation, suggesting a therapeutic effect of everolimus on these 
lesions. Abdominal HRCT at 3 months of treatment also demonstrated a 
decreased density of all AMLs. 
3. Discussion 
MMPH was first described in 1991 on open-lung biopsy in a 38-year 
old female with TSC [5]. Except for rare sporadic cases [6,7], MMPH 
seems systematically associated with TSC, with or without concomitant 
LAM. Unlike LAM, which predominantly affects women, MMPH has no 
gender predilection [8,9]. Its exact prevalence is unknown, but pulmo-
nary changes consistent with MMPH have been found on chest imaging 
in >50% of patients with TSC in large series [8–10]. 
Classical imaging features of MMPH include multiple well-delimited 
solid nodules or poorly defined nodular ground glass opacities, often 
with areas of increased density corresponding to papillary growth 
pattern of type II pneumocytes [8,11,12]. Target-appearing lesions 
corresponding to ground-glass nodules with increased density in the 
periphery have also been reported [8]. The lesions typically range from 
1 to 10 mm in diameter and are diffusely scattered throughout the lungs 
in a random distribution, and less commonly with upper lobe or pe-
ripheral predominance [8,11,12]. 
Histologically, MMPH consists of well-delimited multicentric areas 
of hyperplasia and proliferation of benign type II pneumocytes lining the 
alveolar septa, with preserved alveolar architecture and an associated 
increase in alveolar macrophages, together with adjacent mild fibrotic 
interstitial thickening and lymphocytic infiltrates [6]. MMPH lesions 
exhibit positive staining for cytokeratin, epithelial membrane antigen 
and surfactant proteins, which supports their epithelial origin. Negative 
staining for monoclonal antibody HMB-45 and actin confirms that 
MMPH is distinct from LAM [6,12]. 
MMPH is usually asymptomatic, does not impact lung function, and 
does not significantly progress over time [8,12–14]. It also does not 
seem to undergo malignant transformation [6]. Therefore, with the 
exception of one reported case of progressive MMPH in TSC [15], the 
condition does not appear to be clinically relevant in most patients. 
A definite diagnosis of MMPH cannot be made by imaging alone, but 
a history of TSC, the multifocal and random distribution of lesions, their 
stability in size and number over time, and the absence of associated 
respiratory or systemic symptoms are important clues suggesting a 
diagnosis of MMPH. Lung biopsy is usually not performed except for 
atypical radiological findings, or nodules progressing in size or number. 
Given the clinical context, and despite the absence of histological 
confirmation, we considered MMPH as the most likely diagnosis in the 
present case. 
To our knowledge, this is the second ever observation of a thera-
peutic effect of mTOR inhibitors on MMPH. Indeed, a recent brief case 
report of a 25-year old man with TSC also showed a marked reduction of 
MMPH lesions one year after the introduction of everolimus for AMLs 
[16]. We speculate that everolimus exerts an anti-synthetic, anti--
proliferative and pro-apoptotic effect on MMPH lesions similarly to its 
effects on SEGA, renal AMLs, and LAM cells. Why did everolimus 
reduced only nodule density but not nodule size in our case is currently 
unclear. Longer follow-up could provide more information on this issue. 
4. Conclusion 
This case report demonstrates that the constitutive activation of 
mTOR, which characterizes TSC, is also involved in the pathogenesis of 
MMPH, and that pharmacological inhibition of mTOR could be benefi-
cial in this condition. 
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